Peginterferon alfa-2b biosimilar (Nanogen Biopharmaceutical Co)

聚乙二醇干扰素α-2b生物类似药 (Nanogen Biopharmaceutical Co)

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePeginterferon alfa-2b biosimilar (Nanogen Biopharmaceutical Co)
Drug Alias Name聚乙二醇干扰素α-2b生物仿制药 (Nanogen Biopharmaceutical Co)Pegstat
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsHepatitis CHepatitis BHIV Infections
Global Approved IndicationsHepatitis CHepatitis B
Approved Indications in ChinaN/A
Original Approved Country/TerritoryVietnam
Original Approved Date2016/01/01
Country/TerritoryUnited StatesVietnam
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNanogen Biopharmaceutical Co
China Registration ClassN/A

Develop Information

Active CompaniesNanogen Biopharmaceutical Co
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsHepatitis CHepatitis B
Inactive IndicationsHIV Infections

Other Information

ATC CodeL03AB10
Related LinksN/A